"Expectations were already low for Lilly’s Alzheimer’s drugs because of so many past failures in the field, said Michael P. Krensavage, manager of Krensavage Partners, a hedge fund that owns Lilly shares.
The failure is “clearly another blow to their weak pipeline, and it increases the pressure on them to make some sort of acquisition,’’ said Jon
--more--"
